Refile: BUZZ-'Overall a relief': TrumpRx price cuts deals boost European pharma stocks

Ambu A/S

01/10/2025 09:21

Removes extraneous word from headline

** Shares in European pharma companies jump after U.S. president Donald Trump's decision to sell certain Medicaid drugs at lowered prices via TrumpRx

** The pan-European pharma index .SXDP rises 2.7%, with Ambu AMBUb.CO, Sartorius  SATG.DE and its French unit Stedim Biotech STDM.PA, AstraZeneca AZN.L, Roche ROG.S, Merck MRCG.DE and Argenx ARGX.BR among the biggest gainers

** The news is "overall a relief for the pharma sector," says Bernstein analyst Florent Cespedes, as price cuts will account for less than 15% of U.S. market, in an already low-price scheme, and will mean expedited regulatory approval

** "Trump and his administration promised that pharma companies agreeing to equalise drug pricing across US/ex-US regions will see future drug regulatory reviews expedited," Berenberg analysts say

** Cespedes adds the companies investing in the U.S. "should be on the safe side" after last week's tariff news, highlighting around $200 bln investments already announced by European names

 (Reporting by Dimitri Rhodes)

 ((Dimitri.rhodes@thomsonreuters.com))